AN2 Therapeutics (ANTX) Non-cash Items (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Non-cash Items data on file, last reported at $4.2 million in Q1 2026.

• Non-cash Items for Q1 2026 came in at $4.2 million, down 44.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 million (down 44.31% YoY), and the FY2025 annual result was $170000.0, down 48.48% from the prior year.
• Non-cash Items improved to $4.2 million in Q1 2026 per ANTX's latest filing, from $170000.0 in the prior quarter.
• Over five years, Non-cash Items peaked at $37.9 million in Q4 2023 and troughed at $133000.0 in Q2 2025.
• A 5-year average of $7.5 million and a median of $4.2 million in 2026 frame the typical range for Non-cash Items.
• The sharpest annual moves came in 2023 and 2025: Non-cash Items surged 660.15% in 2023, then plunged 99.26% in 2025.
• A 5-year view of Non-cash Items shows it stood at $5.8 million in 2022, then jumped by 553.43% to $37.9 million in 2023, then sank by 99.13% to $330000.0 in 2024, then slumped by 48.48% to $170000.0 in 2025, then surged by 2389.8% to $4.2 million in 2026.
• Business Quant data shows ANTX's Non-cash Items at $4.2 million in Q1 2026, $170000.0 in Q4 2025, and $3.7 million in Q3 2025.